Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations
Interest in preventative dietary interventions for human health has increasingly focused on the endocannabinoid (eCB)-like compound palmitoylethanolamide (PEA), a bioactive lipid mediator with anti-inflammatory, analgesic, and neuroprotective properties. This Preferred Reporting Items for Systematic...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Brain, Behavior, & Immunity - Health |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666354624002059 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586203913781248 |
|---|---|
| author | R. Bortoletto C. Comacchio M. Garzitto F. Piscitelli M. Balestrieri M. Colizzi |
| author_facet | R. Bortoletto C. Comacchio M. Garzitto F. Piscitelli M. Balestrieri M. Colizzi |
| author_sort | R. Bortoletto |
| collection | DOAJ |
| description | Interest in preventative dietary interventions for human health has increasingly focused on the endocannabinoid (eCB)-like compound palmitoylethanolamide (PEA), a bioactive lipid mediator with anti-inflammatory, analgesic, and neuroprotective properties. This Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020-compliant systematic review aimed at collecting and comprehensively discussing all available data from Randomized Controlled Trials (RCTs) evaluating the efficacy and tolerability of PEA supplementation across human illnesses in patient populations. Overall, 48 eligible outputs from 47 RCTs were extracted, covering neuropsychiatric (n = 15), neurological (n = 17), somatic (n = 13), and visceral (n = 11) disturbances, as well as PEA effects on blood/plasma or other tissue biomarkers (n = 10). The strongest evidence emerged from RCTs exploring PEA impact on pain management and measures of general wellbeing, especially in its ultramicronized/micronized or cold-water dispersible formulations, showing good tolerability compared to controls. Also, alongside symptom improvement, PEA demonstrated to modulate biomarkers early altered in the initial phases of an illness or contributing to its progression, suggesting a disease-modifying potential. This systematic review provided a comprehensive overview of the therapeutic potential of PEA across RCTs, highlighting its versatility either as monotherapy or add-on treatment for various clinical conditions. |
| format | Article |
| id | doaj-art-775d9637d3ff42d6941d3809742f6ce7 |
| institution | Kabale University |
| issn | 2666-3546 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Brain, Behavior, & Immunity - Health |
| spelling | doaj-art-775d9637d3ff42d6941d3809742f6ce72025-01-26T05:05:01ZengElsevierBrain, Behavior, & Immunity - Health2666-35462025-02-0143100927Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populationsR. Bortoletto0C. Comacchio1M. Garzitto2F. Piscitelli3M. Balestrieri4M. Colizzi5Unit of Psychiatry and Eating Disorders, Department of Medicine (DMED), University of Udine, Udine, Italy; Corresponding author. Unit of Psychiatry and Eating Disorders, Department of Medicine (DMED), University of Udine, 33100, Udine, Italy.Unit of Psychiatry and Eating Disorders, Department of Medicine (DMED), University of Udine, Udine, ItalyUnit of Psychiatry and Eating Disorders, Department of Medicine (DMED), University of Udine, Udine, ItalyInstitute of Biomolecular Chemistry, National Research Council (CNR), Pozzuoli, ItalyUnit of Psychiatry and Eating Disorders, Department of Medicine (DMED), University of Udine, Udine, ItalyUnit of Psychiatry and Eating Disorders, Department of Medicine (DMED), University of Udine, Udine, Italy; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UKInterest in preventative dietary interventions for human health has increasingly focused on the endocannabinoid (eCB)-like compound palmitoylethanolamide (PEA), a bioactive lipid mediator with anti-inflammatory, analgesic, and neuroprotective properties. This Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020-compliant systematic review aimed at collecting and comprehensively discussing all available data from Randomized Controlled Trials (RCTs) evaluating the efficacy and tolerability of PEA supplementation across human illnesses in patient populations. Overall, 48 eligible outputs from 47 RCTs were extracted, covering neuropsychiatric (n = 15), neurological (n = 17), somatic (n = 13), and visceral (n = 11) disturbances, as well as PEA effects on blood/plasma or other tissue biomarkers (n = 10). The strongest evidence emerged from RCTs exploring PEA impact on pain management and measures of general wellbeing, especially in its ultramicronized/micronized or cold-water dispersible formulations, showing good tolerability compared to controls. Also, alongside symptom improvement, PEA demonstrated to modulate biomarkers early altered in the initial phases of an illness or contributing to its progression, suggesting a disease-modifying potential. This systematic review provided a comprehensive overview of the therapeutic potential of PEA across RCTs, highlighting its versatility either as monotherapy or add-on treatment for various clinical conditions.http://www.sciencedirect.com/science/article/pii/S2666354624002059Peroxisome proliferator-activated receptor αGlutamateNeuroinflammationNutraceuticalEndocannabinoidomeCannabidiol |
| spellingShingle | R. Bortoletto C. Comacchio M. Garzitto F. Piscitelli M. Balestrieri M. Colizzi Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations Brain, Behavior, & Immunity - Health Peroxisome proliferator-activated receptor α Glutamate Neuroinflammation Nutraceutical Endocannabinoidome Cannabidiol |
| title | Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations |
| title_full | Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations |
| title_fullStr | Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations |
| title_full_unstemmed | Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations |
| title_short | Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations |
| title_sort | palmitoylethanolamide supplementation for human health a state of the art systematic review of randomized controlled trials in patient populations |
| topic | Peroxisome proliferator-activated receptor α Glutamate Neuroinflammation Nutraceutical Endocannabinoidome Cannabidiol |
| url | http://www.sciencedirect.com/science/article/pii/S2666354624002059 |
| work_keys_str_mv | AT rbortoletto palmitoylethanolamidesupplementationforhumanhealthastateoftheartsystematicreviewofrandomizedcontrolledtrialsinpatientpopulations AT ccomacchio palmitoylethanolamidesupplementationforhumanhealthastateoftheartsystematicreviewofrandomizedcontrolledtrialsinpatientpopulations AT mgarzitto palmitoylethanolamidesupplementationforhumanhealthastateoftheartsystematicreviewofrandomizedcontrolledtrialsinpatientpopulations AT fpiscitelli palmitoylethanolamidesupplementationforhumanhealthastateoftheartsystematicreviewofrandomizedcontrolledtrialsinpatientpopulations AT mbalestrieri palmitoylethanolamidesupplementationforhumanhealthastateoftheartsystematicreviewofrandomizedcontrolledtrialsinpatientpopulations AT mcolizzi palmitoylethanolamidesupplementationforhumanhealthastateoftheartsystematicreviewofrandomizedcontrolledtrialsinpatientpopulations |